Skip to content

Culturally Tailoring an Advance Care Planning Intervention for American Indians

Culturally Tailoring an Advance Care Planning Intervention for American Indians

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05304117
Enrollment
155
Registered
2022-03-31
Start date
2022-02-04
Completion date
2024-03-08
Last updated
2025-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advance Care Planning

Keywords

American Indian, Advance Care Planning, Serious illness, end-of-life care

Brief summary

This project has three specific aims: (1) culturally tailor the content of the Make Your Wishes about You (MY WAY) ACP curriculum and guide for one American Indian tribe; (2) assess the feasibility of the culturally-tailored MY WAY ACP curriculum and patient education guide with the tribe; and (3) examine preliminary outcomes of the culturally-tailored MY WAY ACP curriculum and guide with 70 tribal members. Upon successful completion, it is expected that this project will develop a feasible culturally-tailored MY WAY that through a quasi-experimental waitlist design shows promise as an efficacious program with respect to self-efficacy, readiness, and ACP completion that increases facilitators and decreases barriers to ACP.

Detailed description

Research Design. A quasi-experimental waitlist study design will be used to test the hypothesis that the intervention participants will experience increased ACP self-efficacy, readiness, and completion rates. It is also expected that the intervention participants will experience increased facilitators and decreased barriers to ACP. A control sample of waitlist participants will be used. Based on the odds of completing an ACP indicated in previously implemented MY WAY interventions and using 90% power as a threshold, it is estimated that will be a need for at least an n = 60 to find effects. The intervention group, Cohort 1, will be those who participated in the first round of both the Community Educational Sessions and Sharing Sessions. The control group, Cohort 2, will be those who participated in the second round of both the Community Education Sessions and Sharing Sessions. Measurement. Process Measures that are a part of the 9-item ACP Engagement Survey that includes measurement of self-efficacy and readiness, identified from Behavioral Change Theory, will be used. Self-efficacy and readiness subscales have Likert responses of not at all, a little, somewhat, fairly, extremely and have good reliability and discriminant validity. Barriers and Facilitators to ACP Questionnaire used in the MY WAY randomized controlled trial will be used. Pretest interviews with these measurements will be conducted by telephone or in person at the time of pre-registration for both cohorts by the Project Coordinator and team members. Cohort 1 will be interviewed five times: Baseline pretest, Community Information Session Evaluation; Sharing Session Evaluation, 8 week-post test and 6 month post-test. Cohort 2 will be interviewed five times: Baseline pretest, 2nd baseline control pretest, waitlist Community Information Session evaluation, and waitlist Sharing Session evaluation, 8 week post test. The first interview at registration will serve as baseline for the waitlist group, Cohort 2. Cohort 2 will be contacted again approximately 6 months later and two-weeks prior to the second Community Education Session to remind them of their registration and to re-interview them for their intervention pretest. Posttest interviews will also be conducted by the Project Coordinator eight weeks post Sharing Session for both groups to capture ACP self-efficacy, readiness, and completion rates. Statistical Analyses. Demographic characteristics will be examined using descriptive statistics (frequencies, measures of central tendency, measures of variation) and stratified analyses (e.g., delineating measures by demographics, attendance, ACP agreement etc.) to examine the association between demographics and program outcomes. ACP Engagement and the Barriers and Facilitators to ACP Questionnaire (ACP measures) will be compared between those who do and do not engage in Sharing Sessions and between Cohort 1 and Cohort 2. The tribal community as well as location of Community Education Session will be included in all analyses as nested participant variables to ensure that differences between tribal communities and education delivery do not significantly change results. To account for these nested variables, hierarchical linear modeling or a similar method will be used in comparison analyses. It is likely that there will be significant attrition from Community Education Sessions to Sharing Sessions. A Heckman Selectivity analyses will be used to determine if there are differences between those who complete the full intervention and those who complete only baseline measures or Community Educational Sessions. Due to the nature of the study, there may also be attrition due to death. If there are differences in attrition, the inverse Mill's ratio will be used in all further analyses. Comparison of baseline measures from pre-registration interviews will serve to ensure that there are no significant differences between the cohorts. After these preliminary analyses, change in Cohort 1's ACP measures can be compared to changes from baseline to the waitlist pretest measures from Cohort 2. Since Cohort 2 received no intervention in the first 6 months, the analysis will control for natural variations over time and any measures which show significantly larger change in Cohort 1 can be attributed to the intervention. Cohorts 1 and 2 can then be combined to examine intervention effects (i.e., change from pretest to posttest) in the full sample of participants who experienced the Sharing Sessions; baseline results for Cohort 1 will be combined with waitlist pretest results for Cohort 2 and compared to the combined group of 70 Sharing Sessions' posttests. Finally, the combined cohorts will be compared to a subsample of matched participants who experienced the Community Education Sessions only to determine how each step in MY WAY affects the outcome ACP measures.

Interventions

BEHAVIORALAdvance Care Planning

Community Information Session and Private Sharing Session with trained social worker

Sponsors

Pacific Institute for Research and Evaluation
CollaboratorOTHER
National Institute of Nursing Research (NINR)
CollaboratorNIH
Western Carolina University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* aged ≥18 years * either enrolled member or spouse of enrolled member in tribal service area * Member of another American Indian/Alaskan Native tribe * English fluency * Resides in the tribal service area.

Exclusion criteria

• Cognitively impaired

Design outcomes

Primary

MeasureTime frameDescription
Count of Self-Report of Advance DirectiveCohort 1 Experimental: Baseline and Post-test (week 8); Cohort 2 Waitlist: Baseline 1 and Baseline 2 (3-6 months after baseline and immediately before intervention); Cohort 2 Experimental; Baseline 1 and post-test (5-8 months after 1st baseline)The proportion of participants who self-report advance directive completion.
Average Advance Care Planning -Engagement ReadinessCohort 1 Experimental: Baseline and Post-test (week 8); Cohort 2 Waitlist: Baseline 1 and Baseline 2 (3-6 months after baseline and immediately before intervention); Cohort 2 Experimental; Baseline 1 and post-test (5-8 months after 1st baseline)The mean ACP Readiness scores range from 1-6, with higher scores indicating greater readiness.
Average Advance Care Planning-Engagement Self-EfficacyCohort 1 Experimental: Baseline and Post-test (week 8); Cohort 2 Waitlist: Baseline 1 and Baseline 2 (3-6 months after baseline and immediately before intervention); Cohort 2 Experimental; Baseline 1 and post-test (5-8 months after 1st baseline)The mean ACP Self-Efficacy scores range from 1-6, with higher scores indicating greater self-efficacy. not at all, a little, somewhat, fairly, extremely Higher scores indicate better outcomes.

Secondary

MeasureTime frameDescription
Average Number of Barriers to Advance Care PlanningCohort 1 Experimental: Baseline and Post-test (week 8); Cohort 2 Waitlist: Baseline 1 and Baseline 2 (3-6 months after baseline and immediately before intervention); Cohort 2 Experimental; Baseline 1 and post-test (5-8 months after 1st baseline)The sum (0-8) ACP Barriers Score with higher scores indicating more barriers.
Average Number of Facilitators for Advance Care PlanningCohort 1 Experimental: Baseline and Post-test (week 8); Cohort 2 Waitlist: Baseline 1 and Baseline 2 (3-6 months after baseline and immediately before intervention); Cohort 2 Experimental; Baseline 1 and post-test (5-8 months after 1st baseline)The sum (0-8) of ACP Facilitators Score , with higher scores indicating more facilitators.

Countries

United States

Participant flow

Participants by arm

ArmCount
Advance Care Planning Experimental
Community Information Session on advance care planning and private one-on-one Sharing Session about advance care planning. Advance Care Planning: Community Information Session and Private Sharing Session with trained social worker
114
Advance Care Planning Waitlist
Waitlist Group- Baseline control measures will be collected at the same time as Cohort 1 completes their pretest. Six Months after Cohort 1, participants will be pretested again before attending a Community Information Session on advance care planning and an one-on-one Sharing Session about Advance Care Planning. Advance Care Planning: Community Information Session and Private Sharing Session with trained social worker
41
Total155

Baseline characteristics

CharacteristicAdvance Care Planning ExperimentalAdvance Care Planning WaitlistTotal
Advance Care Plans10 Participants8 Participants18 Participants
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
69 Participants28 Participants97 Participants
Age, Categorical
Between 18 and 65 years
45 Participants13 Participants58 Participants
Age, Continuous63.93 years
STANDARD_DEVIATION 16.7
68.3 years
STANDARD_DEVIATION 13.8
64.82 years
STANDARD_DEVIATION 15.37
Race (NIH/OMB)
American Indian or Alaska Native
96 Participants35 Participants131 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
18 Participants6 Participants24 Participants
Race (NIH/OMB)
White
0 Participants0 Participants0 Participants
Region of Enrollment
United States
114 participants41 participants155 participants
Sex: Female, Male
Female
81 Participants28 Participants109 Participants
Sex: Female, Male
Male
33 Participants13 Participants46 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
3 / 1050 / 41
other
Total, other adverse events
0 / 1050 / 41
serious
Total, serious adverse events
0 / 1050 / 41

Outcome results

Primary

Average Advance Care Planning -Engagement Readiness

The mean ACP Readiness scores range from 1-6, with higher scores indicating greater readiness.

Time frame: Cohort 1 Experimental: Baseline and Post-test (week 8); Cohort 2 Waitlist: Baseline 1 and Baseline 2 (3-6 months after baseline and immediately before intervention); Cohort 2 Experimental; Baseline 1 and post-test (5-8 months after 1st baseline)

ArmMeasureGroupValue (MEAN)Dispersion
Advance Care Planning Experimental (Cohort 1)Average Advance Care Planning -Engagement ReadinessBaseline3.20 score on a scaleStandard Deviation 1.01
Advance Care Planning Experimental (Cohort 1)Average Advance Care Planning -Engagement Readinesspost-test4.12 score on a scaleStandard Deviation 0.8
Advance Care Planning Waitlist (Cohort 2)Average Advance Care Planning -Engagement ReadinessBaseline3.26 score on a scaleStandard Deviation 1.05
Advance Care Planning Waitlist (Cohort 2)Average Advance Care Planning -Engagement Readinesspost-test3.56 score on a scaleStandard Deviation 0.87
Advance Care Planning Experimental Cohort 2Average Advance Care Planning -Engagement ReadinessBaseline3.26 score on a scaleStandard Deviation 1.05
Advance Care Planning Experimental Cohort 2Average Advance Care Planning -Engagement Readinesspost-test4.26 score on a scaleStandard Deviation 0.76
Primary

Average Advance Care Planning-Engagement Self-Efficacy

The mean ACP Self-Efficacy scores range from 1-6, with higher scores indicating greater self-efficacy. not at all, a little, somewhat, fairly, extremely Higher scores indicate better outcomes.

Time frame: Cohort 1 Experimental: Baseline and Post-test (week 8); Cohort 2 Waitlist: Baseline 1 and Baseline 2 (3-6 months after baseline and immediately before intervention); Cohort 2 Experimental; Baseline 1 and post-test (5-8 months after 1st baseline)

ArmMeasureGroupValue (MEAN)Dispersion
Advance Care Planning Experimental (Cohort 1)Average Advance Care Planning-Engagement Self-EfficacyBaseline4.33 score on a scaleStandard Deviation 0.93
Advance Care Planning Experimental (Cohort 1)Average Advance Care Planning-Engagement Self-Efficacy8 weeks5.29 score on a scaleStandard Deviation 0.85
Advance Care Planning Waitlist (Cohort 2)Average Advance Care Planning-Engagement Self-EfficacyBaseline4.28 score on a scaleStandard Deviation 0.99
Advance Care Planning Waitlist (Cohort 2)Average Advance Care Planning-Engagement Self-Efficacy8 weeks4.84 score on a scaleStandard Deviation 0.87
Advance Care Planning Experimental Cohort 2Average Advance Care Planning-Engagement Self-EfficacyBaseline4.28 score on a scaleStandard Deviation 0.99
Advance Care Planning Experimental Cohort 2Average Advance Care Planning-Engagement Self-Efficacy8 weeks5.56 score on a scaleStandard Deviation 0.42
Primary

Count of Self-Report of Advance Directive

The proportion of participants who self-report advance directive completion.

Time frame: Cohort 1 Experimental: Baseline and Post-test (week 8); Cohort 2 Waitlist: Baseline 1 and Baseline 2 (3-6 months after baseline and immediately before intervention); Cohort 2 Experimental; Baseline 1 and post-test (5-8 months after 1st baseline)

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Advance Care Planning Experimental (Cohort 1)Count of Self-Report of Advance DirectiveBaseline10 Participants
Advance Care Planning Experimental (Cohort 1)Count of Self-Report of Advance DirectiveCohort 1-8 weeks after intervention; Cohort 2- 3-6 months after baseline but before intervention67 Participants
Advance Care Planning Experimental (Cohort 1)Count of Self-Report of Advance DirectiveCohort 1- 6 months after intervention; Cohort 2- 8 weeks after intervention67 Participants
Advance Care Planning Waitlist (Cohort 2)Count of Self-Report of Advance DirectiveBaseline5 Participants
Advance Care Planning Waitlist (Cohort 2)Count of Self-Report of Advance DirectiveCohort 1-8 weeks after intervention; Cohort 2- 3-6 months after baseline but before intervention6 Participants
Advance Care Planning Waitlist (Cohort 2)Count of Self-Report of Advance DirectiveCohort 1- 6 months after intervention; Cohort 2- 8 weeks after intervention29 Participants
Secondary

Average Number of Barriers to Advance Care Planning

The sum (0-8) ACP Barriers Score with higher scores indicating more barriers.

Time frame: Cohort 1 Experimental: Baseline and Post-test (week 8); Cohort 2 Waitlist: Baseline 1 and Baseline 2 (3-6 months after baseline and immediately before intervention); Cohort 2 Experimental; Baseline 1 and post-test (5-8 months after 1st baseline)

ArmMeasureGroupValue (MEAN)Dispersion
Advance Care Planning Experimental (Cohort 1)Average Number of Barriers to Advance Care PlanningBaseline1.96 score on a scaleStandard Deviation 1.93
Advance Care Planning Experimental (Cohort 1)Average Number of Barriers to Advance Care PlanningPost-test1.44 score on a scaleStandard Deviation 1.97
Advance Care Planning Waitlist (Cohort 2)Average Number of Barriers to Advance Care PlanningBaseline2.39 score on a scaleStandard Deviation 2.23
Advance Care Planning Waitlist (Cohort 2)Average Number of Barriers to Advance Care PlanningPost-test1.44 score on a scaleStandard Deviation 1.6
Advance Care Planning Experimental Cohort 2Average Number of Barriers to Advance Care PlanningBaseline2.39 score on a scaleStandard Deviation 2.23
Advance Care Planning Experimental Cohort 2Average Number of Barriers to Advance Care PlanningPost-test1.11 score on a scaleStandard Deviation 1.31
Secondary

Average Number of Facilitators for Advance Care Planning

The sum (0-8) of ACP Facilitators Score , with higher scores indicating more facilitators.

Time frame: Cohort 1 Experimental: Baseline and Post-test (week 8); Cohort 2 Waitlist: Baseline 1 and Baseline 2 (3-6 months after baseline and immediately before intervention); Cohort 2 Experimental; Baseline 1 and post-test (5-8 months after 1st baseline)

ArmMeasureGroupValue (MEAN)Dispersion
Advance Care Planning Experimental (Cohort 1)Average Number of Facilitators for Advance Care PlanningBaseline5.65 score on a scaleStandard Deviation 1.44
Advance Care Planning Experimental (Cohort 1)Average Number of Facilitators for Advance Care PlanningPost-test6.52 score on a scaleStandard Deviation 1.43
Advance Care Planning Waitlist (Cohort 2)Average Number of Facilitators for Advance Care PlanningBaseline6.24 score on a scaleStandard Deviation 1.2
Advance Care Planning Waitlist (Cohort 2)Average Number of Facilitators for Advance Care PlanningPost-test5.95 score on a scaleStandard Deviation 1.55
Advance Care Planning Experimental Cohort 2Average Number of Facilitators for Advance Care PlanningBaseline6.24 score on a scaleStandard Deviation 1.2
Advance Care Planning Experimental Cohort 2Average Number of Facilitators for Advance Care PlanningPost-test5.19 score on a scaleStandard Deviation 1.27

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026